Dr. Mammen is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
4940 Eastern Ave
Baltimore, MD 21224Phone+1 410-550-5624
Education & Training
- Johns Hopkins UniversityFellowship, Clinical Neurophysiology, 2004 - 2005
- Johns Hopkins UniversityResidency, Neurology, 2001 - 2004
- Johns Hopkins UniversityInternship, Internal Medicine, 2000 - 2001
- Johns Hopkins University School of MedicineClass of 2000
Certifications & Licensure
- MD State Medical License 2004 - 2025
- American Board of Psychiatry and Neurology Neurology
- American Board of Psychiatry and Neurology Neuromuscular Medicine
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013-2014
Publications & Presentations
PubMed
- Precise identification and tracking of HMGCR-reactive CD4+ T cells in the target tissue of patients with anti-HMGCR immune-mediated necrotising myopathy.Eleni Tiniakou, Alex Girgis, Tiara Siafei, Jemima Albayda, Brittany Adler
Annals of the Rheumatic Diseases. 2025-02-01 - Immune Checkpoint Inhibitor Myopathy: The Double-Edged Sword of Cancer Immunotherapy.Grayson Beecher, Iago Pinal-Fernandez, Andrew L Mammen, Teerin Liewluck
Neurology. 2024-12-10 - 1 citationsRecent Updates on the Pathogenesis of Inflammatory Myopathies.Jon Musai, Andrew L Mammen, Iago Pinal-Fernandez
Current Rheumatology Reports. 2024-12-01
Press Mentions
- Ra Pharmaceuticals Announces Expansion of Neuromuscular Portfolio with Clearance of IND Application for Zilucoplan for the Treatment of Immune-Mediated Necrotizing MyopathyJune 4th, 2019
- Update on MyositisOctober 25th, 2018
- Atorvastatin-Induced Necrotizing Autoimmune Myositis: An Emerging Dominant Entity in Patients with Autoimmune Myositis Presenting with a Pure Polymyositis PhenotypeJanuary 23rd, 2017
- Join now to see all
Professional Memberships
- Member
External Links
- Johns Hopkins Physicianshttp://www.hopkinsmedicine.org/andrew-mammen
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: